These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36484652)

  • 1. PARP inhibition promotes endothelial-like traits in melanoma cells and modulates pericyte coverage dynamics during vasculogenic mimicry.
    Fernández-Cortés M; Delgado-Bellido D; Bermúdez-Jiménez E; Paramio JM; O'Valle F; Vinckier S; Carmeliet P; Garcia-Diaz A; Oliver FJ
    J Pathol; 2023 Mar; 259(3):318-330. PubMed ID: 36484652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PARP Inhibitor Olaparib Modulates the Transcriptional Regulatory Networks of Long Non-Coding RNAs during Vasculogenic Mimicry.
    Fernández-Cortés M; Andrés-León E; Oliver FJ
    Cells; 2020 Dec; 9(12):. PubMed ID: 33333852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth.
    Thijssen VL; Paulis YW; Nowak-Sliwinska P; Deumelandt KL; Hosaka K; Soetekouw PM; Cimpean AM; Raica M; Pauwels P; van den Oord JJ; Tjan-Heijnen VC; Hendrix MJ; Heldin CH; Cao Y; Griffioen AW
    J Pathol; 2018 Dec; 246(4):447-458. PubMed ID: 30101525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular regulation of vasculogenic mimicry in human uveal melanoma cells: role of helix-loop-helix Id2 (inhibitor of DNA binding 2).
    Su F; Li B; Wang J; Xu X; Ren R; Li L; Gao F; Liu X
    Graefes Arch Clin Exp Ophthalmol; 2009 Mar; 247(3):411-9. PubMed ID: 19043732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
    Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
    Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasculogenic Mimicry in a 3D Model In Vitro.
    Marques Dos Reis E; Vieira Berti F; Marques Porto L
    Methods Mol Biol; 2022; 2514():39-43. PubMed ID: 35771416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic AMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro.
    Lissitzky JC; Parriaux D; Ristorcelli E; Vérine A; Lombardo D; Verrando P
    Cancer Res; 2009 Feb; 69(3):802-9. PubMed ID: 19176384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation.
    Rodríguez MI; Peralta-Leal A; O'Valle F; Rodriguez-Vargas JM; Gonzalez-Flores A; Majuelos-Melguizo J; López L; Serrano S; de Herreros AG; Rodríguez-Manzaneque JC; Fernández R; Del Moral RG; de Almodóvar JM; Oliver FJ
    PLoS Genet; 2013 Jun; 9(6):e1003531. PubMed ID: 23785295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of transgelin blocks interleukin-8 utilization and suppresses vasculogenic mimicry in breast cancer cells.
    Aikins AR; Kim M; Raymundo B; Kim CW
    Exp Biol Med (Maywood); 2017 Mar; 242(6):573-583. PubMed ID: 28058861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells.
    Chivot J; Ferrand N; Fert A; Van Dreden P; Morichon R; Sabbah M
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor cell vascular mimicry: Novel targeting opportunity in melanoma.
    Hendrix MJ; Seftor EA; Seftor RE; Chao JT; Chien DS; Chu YW
    Pharmacol Ther; 2016 Mar; 159():83-92. PubMed ID: 26808163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications.
    Kirschmann DA; Seftor EA; Hardy KM; Seftor RE; Hendrix MJ
    Clin Cancer Res; 2012 May; 18(10):2726-32. PubMed ID: 22474319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2).
    Hess AR; Seftor EA; Gardner LM; Carles-Kinch K; Schneider GB; Seftor RE; Kinch MS; Hendrix MJ
    Cancer Res; 2001 Apr; 61(8):3250-5. PubMed ID: 11309274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of CD146 lessens uveal melanoma progression through reducing angiogenesis and vasculogenic mimicry.
    Zhang R; Chen X; Chen S; Tang J; Chen F; Lin Y; Reinach PS; Yan X; Tu L; Duan H; Qu J; Hou Q
    Cell Oncol (Dordr); 2022 Aug; 45(4):557-572. PubMed ID: 35716258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas.
    Sun B; Zhang S; Zhao X; Zhang W; Hao X
    Int J Oncol; 2004 Dec; 25(6):1609-14. PubMed ID: 15547697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry.
    Ruf W; Seftor EA; Petrovan RJ; Weiss RM; Gruman LM; Margaryan NV; Seftor RE; Miyagi Y; Hendrix MJ
    Cancer Res; 2003 Sep; 63(17):5381-9. PubMed ID: 14500372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome.
    Tan LY; Mintoff C; Johan MZ; Ebert BW; Fedele C; Zhang YF; Szeto P; Sheppard KE; McArthur GA; Foster-Smith E; Ruszkiewicz A; Brown MP; Bonder CS; Shackleton M; Ebert LM
    Oncotarget; 2016 Jul; 7(29):46492-46508. PubMed ID: 27340778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of microtubule-associated protein-1 light chain 3 is associated with melanoma metastasis and vasculogenic mimicry.
    Han C; Sun B; Wang W; Cai W; Lou D; Sun Y; Zhao X
    Tohoku J Exp Med; 2011 Apr; 223(4):243-51. PubMed ID: 21415575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rictor regulates the vasculogenic mimicry of melanoma via the AKT-MMP-2/9 pathway.
    Liang X; Sun R; Zhao X; Zhang Y; Gu Q; Dong X; Zhang D; Sun J; Sun B
    J Cell Mol Med; 2017 Dec; 21(12):3579-3591. PubMed ID: 28699701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vasculogenic mimicry--potential target for tumor therapy].
    Yue WY; Chen ZP
    Ai Zheng; 2006 Jul; 25(7):914-6. PubMed ID: 16831290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.